EUVIMEDOpdag EUVIMED
Crossref

Apigenin Inhibits Triple‐Negative Breast Cancer Growth by Dual Targeting GPX4 / SLC7A11 ‐Mediated Ferroptosis and PKM2 / GLUT1 ‐Mediated Aerobic Glycolysis

Mingmei Zhu, Danping Peng, Zhongyang Yu, Meng Zhao, Jiajia Liu, Wanlu Yu, Hongyue Xu iD, Baochun Lu iD, Ning Liao, Sijia Niu, Ziyan Liu, Xinhua Cui and 2 more

Phytotherapy Research · 2026-06 · 40 (6) · 3741-3757

DOI: 10.1002/ptr.70337 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2026-04-12. Written by Mingmei Zhu and 13 co-authors. Institution: The First Hospital of Jilin University, Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infect…. Major MEDLINE topics: Apigenin, Ferroptosis, Glucose Transporter Type 1, Glycolysis. Cited 2 times so far (Crossref); 47 references. Funded by: The National Nature Science Foundation of China, Science and Technology Development Plan Project of Jilin Province, China, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Triple‐negative breast cancer (TNBC) is aggressive with limited treatments. Although the natural flavonoid Apigenin (API) shows anti‐tumor potential, its mechanism in TNBC remains unclear. This study investigated API's role in inducing ferroptosis and inhibiting glycolysis to suppress TNBC. Molecular docking predicted API's binding to ferroptosis‐ and glycolysis‐related proteins. In vitro, 4T1 and MDA‐MB‐231 TNBC cells were used to assess API's effects on viability, migration, invasion, and key metabolic markers (Fe 2+ , MDA, ROS, GSH, lactic acid, glucose, ATP, OCR, ECAR), and protein expression (GPX4, SLC7A11, TFR, FPN1, FTH1, FTL, FSP1, PKM2, GLUT1, GLUT4, HK2, LDHA) using RT‐qPCR and Western blotting. In vivo, a 4T1 tumor xenograft model evaluated API's impact on tumor growth, protein expression, and toxicity (H&E staining). Molecular docking indicated good binding affinity of API with ferroptosis‐ and glycolysis‐related proteins. In vitro, API inhibited the viability, migration, and invasion of TNBC cells. API significantly increased Fe 2+ , MDA, and ROS levels while decreasing reduced GSH levels, downregulated GPX4, SLC7A11, FPN1, FTH1, FTL, and FSP1 expression, and upregulated TFR expression, indicating ferroptosis induction. API also decreased lactic acid, ATP, and ECAR levels while increasing intracellular glucose and OCR levels, downregulating PKM2, GLUT1, GLUT4, HK2, and LDHA expression, demonstrating glycolysis inhibition. In vivo, API significantly inhibited tumor growth in the 4T1 xenograft model without obvious toxicity and regulated the expression of ferroptosis and glycolysis‐related proteins. These findings establish API as a promising natural anti‐TNBC drug by simultaneously targeting ferroptosis and aerobic glycolysis.

Subjects

MeSH terms (MEDLINE)

ApigeninFerroptosisGlucose Transporter Type 1GlycolysisPhospholipid Hydroperoxide Glutathione PeroxidaseTriple Negative Breast NeoplasmsAnimalsFemaleHumansMiceCarrier ProteinsCell Line, TumorCell MovementCell ProliferationCell SurvivalMDA-MB-231 CellsMembrane ProteinsMice, Inbred BALB CMolecular Docking SimulationThyroid Hormone-Binding ProteinsThyroid HormonesXenograft Model Antitumor Assays

Author keywords

apigeninferroptosisglycolysistriple negative breast cancer

Substances

ApigeninCarrier ProteinsGlucose Transporter Type 1Membrane ProteinsPhospholipid Hydroperoxide Glutathione PeroxidaseSLC2A1 protein, humanThyroid Hormone-Binding ProteinsThyroid Hormones

Authors and institutions

  • The First Hospital of Jilin University, Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of…
  • State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Cardiology, Jilin Airport Hospital, Jilin, China.

ORCID profiles: Hongyue Xu, Baochun Lu

Funding

  • The National Nature Science Foundation of China
  • Science and Technology Development Plan Project of Jilin Province, China
  • National Natural Science Foundation of China

Cite

APA

Zhu, M., Peng, D., Yu, Z., Zhao, M., Liu, J., Yu, W., Xu, H., Lu, B., Liao, N., Niu, S., Liu, Z., Cui, X., Yu, L., & Wang, Y. (2026). Apigenin Inhibits Triple‐Negative Breast Cancer Growth by Dual Targeting GPX4 / SLC7A11 ‐Mediated Ferroptosis and PKM2 / GLUT1 ‐Mediated Aerobic Glycolysis. Phytotherapy Research, 40(6), 3741-3757. https://doi.org/10.1002/ptr.70337

Vancouver

Zhu M, Peng D, Yu Z, Zhao M, Liu J, Yu W, et al. Apigenin Inhibits Triple‐Negative Breast Cancer Growth by Dual Targeting GPX4 / SLC7A11 ‐Mediated Ferroptosis and PKM2 / GLUT1 ‐Mediated Aerobic Glycolysis. Phytotherapy Research. 2026;40(6):3741-3757. doi:10.1002/ptr.70337

BibTeX
@article{Zhu2026,
  author = {Zhu, Mingmei and Peng, Danping and Yu, Zhongyang and Zhao, Meng and Liu, Jiajia and Yu, Wanlu and Xu, Hongyue and Lu, Baochun and Liao, Ning and Niu, Sijia and Liu, Ziyan and Cui, Xinhua and Yu, Lu and Wang, Yang},
  title = {Apigenin Inhibits Triple‐Negative Breast Cancer Growth by Dual Targeting GPX4 / SLC7A11 ‐Mediated Ferroptosis and PKM2 / GLUT1 ‐Mediated Aerobic Glycolysis},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3741--3757},
  doi = {10.1002/ptr.70337}
}
Start for free →